[ad_1]
SCB-2019 (S-Trimer COVID-19 Vaccine) SCB-2019 is a recombinant subunit vaccine candidate for COVID-19. Using its proprietary Trimer-Tag © technology, Clover has produced an S-Trimer subunit vaccine candidate that resembles the native trimeric viral spike through the mammalian cell culture production system. Image from Clover Biopharmaceuticals website
MANILA, Philippines – A COVID-19 vaccine from another Chinese pharmaceutical company passed the evaluation of the country’s panel of vaccine experts, making it the second Chinese COVID-19 vaccine to advance the application for a clinical trial.
Dr. Jaime Montoya, Executive Director of the Health Research and Development Council of the Department of Science and Technology, said that China’s Clover Biopharmaceuticals has passed the technical review of the Philippine vaccine expert panel.
Your application was then submitted to the Ethics Review Board for review and to the Food and Drug Administration before you can conduct a clinical trial in the country.
The first vaccine to pass the panel of vaccine experts is China’s Sinovac Biotech, the application of which was approved by the panel sometime in October.
“Sinovac has completed a technical review. There is a company that has carried out a technical review. This is Clover Biopharmaceuticals, ”Montoya said in an online forum.
(Sinovac has now finished its technical review by the panel of vaccine experts. Another company, Clover Biopharmaceuticals, is also finished.)
“So those two and that has already been submitted to the Ethics Review Board,” he added.
(So that’s two firms and both have submitted their application to the Ethics Review Board.)
If all goes well, Montoya said both firms could begin their clinical trials in late December or early January.
The Philippines is in talks with 17 drug makers for a possible COVID-19 vaccine, Montoya said, five of whom have already submitted their application to conduct a clinical trial in the country.
EDV
Read next
Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer and more than 70 other titles, share up to 5 gadgets, listen to the news, download from 4am and share articles on social media. Call 896 6000.
For comments, complaints or inquiries, please contact us.
[ad_2]
